1354961-13-9

Basic information

• Product Name: tert-butyl 5-chloro-2,4-difluorobenzoate
• Synonyms: tert-butyl 5-chloro-2,4-difluorobenzoate
• CAS NO: 1354961-13-9
• Molecular Formula: C₁₁H₁₁ClF₂O₂
• Molecular Weight: 248.6536464
• EINECS: -0
• Mol File: 1354961-13-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 5-chloro-2,4-difluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 5-chloro-2,4-difluorobenzoate(1354961-13-9)
• EPA Substance Registry System: tert-butyl 5-chloro-2,4-difluorobenzoate(1354961-13-9)

Safety Data

• Hazardous Substances Data: 1354961-13-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl 5-chloro-2,4-difluorobenzoate is a chemical compound with the formula C13H14ClF2O2. It is a white solid that is often used in organic synthesis and pharmaceutical research. tert-butyl 5-chloro-2,4-difluorobenzoate is a tert-butyl ester derivative of 5-chloro-2,4-difluorobenzoic acid, and it is commonly used as an intermediate in the production of agrochemicals and pharmaceuticals. Tert-butyl 5-chloro-2,4-difluorobenzoate has potential applications in the development of new drugs and can be used as a building block in the synthesis of various compounds. It is important to handle this chemical with care and follow proper safety protocols due to its potential hazards.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 1355063-69-2 5-chloro-4-{[5-chloro-6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl]oxy}-2-fluoro-N-(methanesulfonyl)benzamide 
• 1355067-24-1 tert-butyl 5-chloro-4-(5-chloro-6-(2,2,3,3-tetrafluoropropoxy)-pyridin-3-yloxy)-2-fluorobenzoate 
• 1354961-11-7 t-butyl-5-chloro-4-(4-chloro-3-(trifluoromethyl)phenoxy)-2-fluorobenzoate 
• 1354955-70-6 5-chloro-4-[4-chloro-3-(trifluoromethyl)phenoxy]-2-fluoro-N-(methylsulfonyl)benzamide 
• 1354960-86-3 5-chloro-4-(4-chloro-3-(trifluoromethyl)phenoxy)-2-fluorobenzoic acid 
• 1354962-92-7 tert-butyl 5-chloro-4-(3-chloro-4-(trifluoromethoxy)-phenoxy)-2-fluorobenzoate 
• 1354955-46-6 5-chloro-4-[-3-chloro-4-(trifluoromethoxy)phenoxy]-2-fluoro-N-(methylsulfonyl)benzamide 
• 1354962-93-8 5-chloro-4-(3-chloro-4-(trifluoromethoxy)-phenoxy)-2-fluorobenzoic acid 
• 1355067-26-3 5-chloro-4-((5-chloro-6-(2,2,3,3-tetrafluoropropoxy)pyridin-3-yl)oxy)-2-fluorobenzoic acid 
• 1446444-52-5 N-(azetidin-1-ylsulfonyl)-5-chloro-4-(3,4-dichlorophenoxy)-2-fluorobenzamide 
• 1446444-71-8 5-chloro-4-(3,4-dichlorophenoxy)-2-fluorobenzoic acid 
• 1446444-70-7 tert-butyl 5-chloro-4-(3,4-dichlorophenoxy)-2-fluorobenzoate 

Relevant articles and documents

Discovery of Acyl-sulfonamide Nav1.7 Inhibitors GDC-0276 and GDC-0310

Nav1.7 is an extensively investigated target for pain with a strong genetic link in humans, yet in spite of this effort, it remains challenging to identify efficacious, selective, and safe inhibitors. Here, we disclose the discovery and preclinical profil

Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (NaV) 1.7 with Potent Analgesic Activity

Herein, we report the discovery and optimization of a series of orally bioavailable acyl sulfonamide NaV1.7 inhibitors that are selective for NaV1.7 over NaV1.5 and highly efficacious in in vivo models of pain and hNaV1.7 target engagement. An analysis of the physicochemical properties of literature NaV1.7 inhibitors suggested that acyl sulfonamides with high fsp3 could overcome some of the pharmacokinetic (PK) and efficacy challenges seen with existing series. Parallel library syntheses lead to the identification of analogue 7, which exhibited moderate potency against NaV1.7 and an acceptable PK profile in rodents, but relatively poor stability in human liver microsomes. Further, design strategy then focused on the optimization of potency against hNaV1.7 and improvement of human metabolic stability, utilizing induced fit docking in our previously disclosed X-ray cocrystal of the NaV1.7 voltage sensing domain. These investigations culminated in the discovery of tool compound 33, one of the most potent and efficacious NaV1.7 inhibitors reported to date.

CHEMICAL COMPOUNDS

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein Het1, X, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain